| Not Yet Recruiting | SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma NCT07374549 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 |
| Not Yet Recruiting | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy NCT07185945 | Guru Sonpavde | Phase 2 |
| Recruiting | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial C NCT07221942 | Fox Chase Cancer Center | Phase 2 |
| Recruiting | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced NCT07241793 | Sun Yat-sen University | Phase 2 |
| Withdrawn | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer NCT05687721 | VA Office of Research and Development | Phase 1 / Phase 2 |
| Active Not Recruiting | A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma NCT07063758 | National Taiwan University Clinical Trial Center | — |
| Recruiting | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma NCT06738251 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Probiotics in Advanced Urothelial Carcinoma NCT06904573 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma NCT06639347 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metast NCT06196736 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 |
| Recruiting | Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma NCT07034053 | Ekaterina Laukhtina | Phase 1 / Phase 2 |
| Recruiting | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer NCT06079112 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma NCT05929235 | Flare Therapeutics Inc. | Phase 1 |
| Withdrawn | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma NCT05738161 | Insel Gruppe AG, University Hospital Bern | Phase 1 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Active Not Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors NCT05544552 | Tyra Biosciences, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lu NCT05318573 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 2 |
| Recruiting | Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC NCT06598761 | Peking University First Hospital | — |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced NCT04856189 | Mamta Parikh | Phase 1 / Phase 2 |
| Unknown | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcino NCT04871334 | Shandong TheraWisdom Biopharma Co., Ltd. | Phase 1 |
| Unknown | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma NCT04603846 | Lee's Pharmaceutical Limited | Phase 1 |
| Withdrawn | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition NCT04064190 | MedPacto, Inc. | Phase 2 |
| Active Not Recruiting | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer NCT02735252 | University of California, San Francisco | N/A |
| Completed | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary T NCT02599324 | Pharmacyclics LLC. | Phase 1 / Phase 2 |
| Unknown | Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma NCT01487915 | Asan Medical Center | Phase 2 |
| Completed | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary NCT00942331 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney NCT00365157 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |